Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 Jun 01; 7(6):895-902.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Esophagogastric Junction
Humans
Microsatellite Instability
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Stomach Neoplasms